Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy

Cassis, Paola; Locatelli, Monica; Corna, Daniela; Villa, Sebastian; Rottoli, Daniela; Cerullo, Domenico; Abbate, Mauro; Remuzzi, Giuseppe; Benigni, Ariela; Zoja, Carla

doi:10.1016/j.kint.2019.04.024

Cited by 35 publications

(48 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, cAng-(1-7) clearly and significantly improved motor functions evaluated by neuroscore, stepping test and body swing test. Sensory motor functions were also sensitive to the treatment with cAng- (1)(2)(3)(4)(5)(6)(7) witnessed by the forelimb placement test. The effect of cAng-(1-7) reached its highest significance in the period of day 29 to 50.…”

Section: Significant Cerebroprotective Actions Of Intracerebroventricmentioning

confidence: 98%

“…Therefore it can not be excluded that cAng-(1-7) passes the BBB early after the stroke induction. Intracerebrally administered Ang- (1)(2)(3)(4)(5)(6)(7) exerts protective effects on the BBB integrity, which may contribute to recovery after cerebral stroke, by regulating the tight junction protein expression [30,48]. Restoration of BBB integrity importantly contributes to reducing stroke-related neurological damage [2].…”

Section: Significant Cerebroprotective Actions Of Intracerebroventricmentioning

confidence: 99%

“…Its prolonged half-life in vivo allows pulmonary delivery. CAng-(1-7) demonstrated therapeutic efficacy in animal models of, amongst others, myocardial infarction, lung fibrosis, neonatal lung injury, pulmonary arterial hypertension, kidney disease and type 1 and 2 diabetes mellitus [7,21,23].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cyclic angiotensin-(1-7) contributes to rehabilitation of animal performance in a rat model of cerebral stroke

Kuipers¹,

Moll

Levy

et al. 2020

Peptides

View full text Add to dashboard Cite

show abstract

Section: Significant Cerebroprotective Actions Of Intracerebroventricmentioning

confidence: 98%

Section: Significant Cerebroprotective Actions Of Intracerebroventricmentioning

confidence: 99%

See 1 more Smart Citation

Cyclic angiotensin-(1-7) contributes to rehabilitation of animal performance in a rat model of cerebral stroke

Kuipers¹,

Moll

Levy

et al. 2020

Peptides

View full text Add to dashboard Cite

show abstract

“…While Ang1-7 has been used in clinical trials for pulmonary hypertension, its short half-life of Ang1-7 constrains therapeutic delivery options (74). Alternative approaches include stabilized forms of Ang1-7, which have demonstrated efficacy in preclinical settings (75).…”

Section: Targeting Ace2 As a Carboxypeptidase To Modulate Inflammatormentioning

confidence: 99%

Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges

Jia¹,

Neptune

Cui

2021

Am J Respir Cell Mol Biol

View full text Add to dashboard Cite

The coronavirus disease (COVID-19) pandemic is sweeping the globe. Even with a number of effective vaccines being approved and available to the public, new cases and escalating mortality are climbing every day. ACE2 (angiotensin-converting enzyme 2) is the primary receptor for the COVID-19 causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its complexation with spike proteins plays a crucial role in viral entry into host cells and the subsequent infection. Blocking this binding event or reducing the accessibility of the virus to the ACE2 receptor, represents an alternative strategy to prevent COVID-19. In addition, the biological significance of ACE2 in modulating the innate immune system and tissue repair cascades and anchors its therapeutic potential for treating the infected patients. In this viewpoint article, we review the current efforts of exploiting ACE2 as a therapeutic target to address this dire medical need. We also provide a holistic view of the pros and cons of each treatment strategy. We highlight the fundamental and translational challenges in moving these research endeavors to clinical applications.

show abstract

“…Using BTBR ob/ob diabetic mice, a model that reproduces characteristic features of human type 2 DN better than other murine models, remarkable renoprotection was obtained after subcutaneous injections of cAng-(1-7) (Cassis et al, 2019a). Cyclic Ang (1-7) treatment, started when mice had already developed albuminuria, significantly limited the progressive increase in albuminuria that was observed in untreated BTBR ob/ob mice.…”

Section: Cyclic Ang-(1-7) and Renoprotection In Diabetic Nephropathymentioning

confidence: 99%

Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets

2020

Self Cite

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes mellitus and the leading cause of end-stage kidney disease. The standard treatments for diabetic patients are glucose and blood pressure control, lipid lowering, and renin-angiotensin system blockade; however, these therapeutic approaches can provide only partial renoprotection if started late in the course of the disease. One major limitation in developing efficient therapies for DN is the complex pathobiology of the diabetic kidney, which undergoes a set of profound structural, metabolic and functional changes. Despite these difficulties, experimental models of diabetes have revealed promising therapeutic targets by identifying pathways that modulate key functions of podocytes and glomerular endothelial cells. In this review we will describe recent advances in the field, analyze key molecular pathways that contribute to the pathogenesis of the disease, and discuss how they could be modulated to prevent or reverse DN.

show abstract

Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy

Cited by 35 publications

References 38 publications

Cyclic angiotensin-(1-7) contributes to rehabilitation of animal performance in a rat model of cerebral stroke

Cyclic angiotensin-(1-7) contributes to rehabilitation of animal performance in a rat model of cerebral stroke

Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges

Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets

Contact Info

Product

Resources

About